Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Durect ( (DRRX) ) has shared an announcement.
On July 28, 2025, Durect Corporation entered into a Merger Agreement with Bausch Health Americas, Inc. and its subsidiary, BHC Lyon Merger Sub, Inc. An amendment to this agreement was made on August 8, 2025, extending the deadline for the tender offer for Durect’s outstanding shares from August 11 to August 12, 2025. This extension may impact the company’s operations and stakeholder interests by providing additional time for the tender process.
The most recent analyst rating on (DRRX) stock is a Buy with a $8.50 price target. To see the full list of analyst forecasts on Durect stock, see the DRRX Stock Forecast page.
Spark’s Take on DRRX Stock
According to Spark, TipRanks’ AI Analyst, DRRX is a Neutral.
Durect’s overall stock score reflects significant financial challenges and unattractive valuation. The merger with Bausch Health offers potential strategic benefits, but the risk of Nasdaq delisting remains a major concern. Mixed technical indicators further complicate the investment outlook.
To see Spark’s full report on DRRX stock, click here.
More about Durect
Average Trading Volume: 1,007,510
Technical Sentiment Signal: Buy
Current Market Cap: $57.74M
For detailed information about DRRX stock, go to TipRanks’ Stock Analysis page.